Cisplatin-Induced Kidney and Hearing Toxicity: Mechanisms and Protective Strategies
This research community investigates the molecular mechanisms behind kidney damage and hearing loss caused by the chemotherapy drug cisplatin, with a primary focus on identifying compounds and pathways that can protect against these side effects.
The work is dominated by studies in animal models, particularly rats and mice, examining how cisplatin triggers oxidative stress, inflammation, and cell death in renal and inner ear tissues. Recurring themes include the role of specific signaling pathways, the protective effects of mesenchymal stem cells, and the development of therapeutic agents that "attenuate" or "ameliorate" cisplatin-induced nephrotoxicity and ototoxicity. While cancer treatment is the context, the core scientific inquiry is into the toxicological mechanisms of the drug itself and the biological responses that can mitigate its damage to vital organs.
The largest share of the community's output is found in platinum research, accounting for 3.8% of all platinum-related papers, with 5,614 papers in this group.
The community comprises 12,138 papers, published most frequently in Frontiers in Pharmacology, Acta Oto-Laryngologica, and Hearing Research.
Recent work continues to focus on acute kidney injury pathogenesis, renal fibrosis mechanisms, and the neurotoxic effects of cancer therapies, including studies on cognitive dysfunction and peripheral neuropathy.